Form 4: Regenxbio Director Kenneth T. Mills Executes Stock Option and Sells Shares

Director Kenneth T. Mills exercised stock options and sold shares of Regenxbio Inc. on May 12, 2025, according to a Form 4 filing.

Summary

• On May 12, 2025, Kenneth T. Mills, a director of REGENXBIO Inc., executed a stock option to acquire 20,602 shares of common stock at a price of $3.76 per share.
• Simultaneously, Mills sold 20,602 shares of common stock at a weighted average price of $7.9141, with prices ranging from $7.66 to $8.04.
• Following these transactions, Mills directly owns 475,103 shares of REGENXBIO Inc. common stock.
• The initial stock option, granting the right to purchase 275,000 shares, vested 25% on May 19, 2016, with the remaining balance vesting in equal monthly installments over the subsequent 36 months.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions. There is no indication of positive or negative outlook.

Industry Context

This filing reflects routine insider trading activity. It is common for company directors to exercise stock options and sell a portion of the acquired shares for personal financial management.

Stakeholder Impact

• The sale of shares by a director could have a minor, short-term impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or long-term prospects.

Key Dates

Keywords

REGENXBIO, Director, Stock Options, Form 4, Share Sale, Beneficial Ownership, RGNX